Specifically, we found that PPP2R1B binds to p-ERK and induces the dephosphorylation of p-ERK and subsequently inhibits the MAPK-ERK signalling pathway both in vitro and in vivo, which suggests that PPP2R1B may be a potential therapeutic target in CRC. The gene discussed is MAPK1; the disease is colorectal carcinoma.